^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RAD51B (RAD51 Paralog B)

    i
    Other names: RAD51B, RAD51 Paralog B, DNA Repair Protein RAD51 Homolog 2, RAD51 Homolog B, RAD51L1, R51H2, RAD51 Homolog B (S. Cerevisiae), RAD51 (S. Cerevisiae)-Like 1, RAD51-Like 1 (S. Cerevisiae), RAD51-Like Protein 1, RecA-Like Protein, Rad51B
    4d
    Epithelioid leiomyosarcoma harboring HMGA2::RAD51B fusion: expanding the spectrum of RAD51B-rearranged uterine sarcoma. (PubMed, Virchows Arch)
    The patient remains disease-free at 4 months. This case expands the molecular spectrum of ELMS and, concomitantly, broadens the emerging morphologic spectrum of RAD51B-rearranged uterine sarcomas, underscoring the diagnostic value of fusion testing in unusual uterine mesenchymal neoplasms.
    Journal
    |
    ER (Estrogen receptor) • RAD51B (RAD51 Paralog B) • HMGA2 (High mobility group AT-hook 2)
    |
    Archer® FusionPlex® Sarcoma kit • FusionPlex® Dx
    11d
    Niraparib in Tumors Metastatic to the CNS (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BAP1 (BRCA1 Associated Protein 1) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • XRCC2 (X-Ray Repair Cross Complementing 2) • RAD54B (RAD54 Homolog B) • XRCC3 (X-Ray Repair Cross Complementing 3)
    |
    HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Zejula (niraparib)
    11d
    NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (clinicaltrials.gov)
    P2, N=32, Recruiting, Rana McKay, MD | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L2 (RAD54 Like 2)
    |
    Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    14d
    Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco) (clinicaltrials.gov)
    P2, N=334, Not yet recruiting, Fudan University
    New P2 trial • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • RAD51 (RAD51 Homolog A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCM (FA Complementation Group M) • RAD52 (RAD52 Homolog DNA Repair Protein) • RPA1 (Replication Protein A1) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    HER-2 negative • PALB2 mutation • PGR positive • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    capecitabine • AiRuiYi (fluzoparib)
    15d
    Rs12516 A allele elevates the risk of colorectal cancer via functional CeRNA network of BDNF-AS, miR-4704-5p and BRCA1. (PubMed, BMC Cancer)
    BRCA1 rs12516 is characterized as a potential biomarker associated with CRC risk, via a possible functional ceRNA network of BDNF-AS, miR-4704-5p and BRCA1. The interaction of a lower expression of BDNF-AS, a higher expression of miR-4704-5p and rs12516 A allele could together increase the risk of colorectal cancer.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • RAD51B (RAD51 Paralog B) • BDNF (Brain Derived Neurotrophic Factor)
    28d
    Characteristics of uterine leiomyosarcoma: a clinicopathological and molecular genetic analysis of twenty-four cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    Secondary morphological changes in uterine leiomyosarcomas associated with hormone therapy pose significant diagnostic challenges. Next generation sequencing can provide valuable evidence for the diagnosis of morphologically challenging cases of leiomyosarcoma in clinical practice.
    Retrospective data • Journal • Tumor mutational burden • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BARD1 (BRCA1 Associated RING Domain 1) • FANCM (FA Complementation Group M) • FANCE (FA Complementation Group E)
    |
    TP53 mutation • TMB-H • TMB-L • RAD51B mutation
    2ms
    Optical Genome Mapping versus Whole-Genome Sequencing in the Clinical Diagnosis of Gynecological Mesenchymal Tumors. (PubMed, J Mol Diagn)
    WGS provides a comprehensive view of the cancer genome, suitable for tumors driven by both single nucleotide variants, SVs, and CNAs. The choice between platforms should be guided by clinical context, diagnostic needs, and available resources.
    Journal
    |
    NF1 (Neurofibromin 1) • TSC2 (TSC complex subunit 2) • RAD51B (RAD51 Paralog B) • HMGA2 (High mobility group AT-hook 2) • PLAG1 (PLAG1 Zinc Finger)
    2ms
    RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion. (PubMed, Cell Death Dis)
    Inhibition of the RAD51B-EZH2 axis allows the re-expression of functional ERα, making TNBC targetable by endocrine therapy. Consistently, the combination of EZH2 inhibitor with tamoxifen effectively reduces TNBC progression, suggesting that the RAD51B-EZH2 axis is a potential therapeutic target for TNBC.
    Journal • BRCA Biomarker
    |
    ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • RAD51B (RAD51 Paralog B)
    |
    FGFR2 mutation
    |
    tamoxifen
    3ms
    Extrauterine RAD51B-Rearranged Soft Tissue Tumors: A Clinicopathologic and Molecular Genetic Study of 10 Cases With Heterogeneous Morphology, Novel Fusions, and a Distinct Methylation Profile. (PubMed, Am J Surg Pathol)
    Despite significant heterogeneity in histology and biological behavior, the shared DNA methylation profile underpins their unified identity. RAD51B-rearranged soft tissue tumors should be included in the differential diagnosis of morphologically undifferentiated or unclassified mesenchymal neoplasms with myogenic differentiation.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • RAD51B (RAD51 Paralog B) • MLANA (Melan-A) • PUM1 (Pumilio RNA Binding Family Member 1)
    3ms
    Cryo-electron microscopy visualization of RAD51 filament assembly and end-capping by XRCC3-RAD51C-RAD51D-XRCC2. (PubMed, Science)
    The RAD51B complex promotes dynamic adenosine triphosphate hydrolysis-dependent assembly of RAD51 filaments, whereas the XRCC3 complex stably caps the 5'-termini of RAD51 filaments to promote homologous pairing, as visualized by cryo-electron microscopy. Highly conserved across evolution, these complexes reveal insights into RAD51 filament formation and capping during DNA repair and replication fork stabilization.
    Journal
    |
    HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • RAD51B (RAD51 Paralog B) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • XRCC2 (X-Ray Repair Cross Complementing 2) • XRCC3 (X-Ray Repair Cross Complementing 3)
    3ms
    Genomic landscape of endometrial polyps. (PubMed, Genome Med)
    Here, we have characterized the genomic landscape of endometrial polyps. We show that chromosomal alterations affecting HMGA1 and HMGA2 are a major underlying cause for polyp development. In addition, we present UBE2A as a novel candidate gene for human tumorigenesis. Our results contribute to a better understanding of endometrial polyp development and pave the way towards the development of targeted, non-invasive treatment options.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • RAD51B (RAD51 Paralog B) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • HMGA1 (High Mobility Group AT-Hook 1) • HMGA2 (High mobility group AT-hook 2) • PLAG1 (PLAG1 Zinc Finger)
    |
    KRAS mutation • PIK3CA mutation • PTEN mutation
    4ms
    Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer. (PubMed, Int J Radiat Oncol Biol Phys)
    Overall, these results suggest that LRR-PCa has a distinct genomic and transcriptomic landscape from de novo prostate cancer. Specifically, LRR-PCa has an enrichment in SNVs in genes associated with tumor aggressiveness and/or DNA repair, has higher Decipher scores, a more basal subtype, and has transcriptomic evidence of lower androgen receptor activity and loss of tumor suppressor genes.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • KMT2C (Lysine Methyltransferase 2C) • ATRX (ATRX Chromatin Remodeler) • FAT1 (FAT atypical cadherin 1) • RAD51B (RAD51 Paralog B)
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay